Report Description

Global Cervical Cancer Vaccine Market Opportunities, 2020

Global Cervical Cancer Vaccine Market Opportunities, 2020
  • Publish Date:November, 2015
  • Format : PDF
  • Pages : 105

 Cervical cancer is mainly caused by Human Papilloma Virus (HPV) infection transmitted via sexual contact with an HPV-infected person. Two strains of HPV that are responsible for causing cervical cancer are HPV 16 and HPV 18. Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Increasing rate of unprotected sex, especially among adolescents, across various developed as well as developing regions, is resulting in growing incidences of cervical cancer, globally. As a result, an increasing number of people, especially females in the age group of 9-26 years, are opting for cervical cancer vaccines. Moreover, reduction in the number of recommended doses of HPV immunisation from three to two, which enhances the uptake of vaccine among a large adolescent female population, is anticipated to drive the global cervical cancer market during 2015 - 2020.

According to Pharmaion report, “Global Cervical Cancer Vaccine Market Opportunities, 2020”, global cervical cancer vaccine market is anticipated to cross US$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. “Global Cervical Cancer Vaccine Market Opportunities, 2020” report elaborates following aspects related to global cervical cancer vaccine market:

·         Global Cervical Cancer Vaccine Market Size, Share & Forecast

·         Segmental Analysis – By Region & By Company

·         Policy & Regulatory Landscape

·         Changing Market Trends & Emerging Opportunities

·         Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

·         To identify the on-going trends and anticipated growth in the next five years

·         To gain competitive knowledge of leading market players

·       To avail 10% customization in the report without any extra charges and get the research data   or trends added in the report as per the buyer’s specific needs      

Report Methodology

The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cervical cancer vaccine producers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.

Please Select Format

Single User License


Single User License Print


Enterprise License


For Queries Please Contact us

[email protected]

+1 646 862 0089

10% Customization